Results 151 to 160 of about 35,059 (247)

Which Anthropometric Index Best Signals 10‑Year Cardiovascular Risk? A Sex‑Stratified Analysis From the Shiraz Heart Study

open access: yesClinical Cardiology, Volume 49, Issue 11, November 2026.
In adults aged 40−70 years, body fat percentage, waist‐to‐height ratio, and waist‐to‐hip ratio were the strongest correlates of elevated 10‐year ASCVD risk, while fat‐free mass showed an inverse association. In younger adults, central adiposity and body fat measures were most strongly associated with higher ASCVD risk.
Mohammad Javad Zibaeenezhad   +16 more
wiley   +1 more source

Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
A systematic review and meta‐analysis of 9 randomised controlled trials (67,662 patients) found that evolocumab significantly improved lipid parameters and reduced major adverse cardiovascular events, myocardial infarction, and coronary revascularisation.
Anika Goel   +10 more
wiley   +1 more source

Circulating Omega‐3 Fatty Acids and Cardiometabolic Outcomes: A Systematic Review of Publications From UK Biobank

open access: yesLipids, Volume 61, Issue 6, Page 783-801, November 2026.
ABSTRACT Studies have shown that omega‐3 fatty acids may protect against cardiovascular diseases (CVDs) and related metabolic conditions. UK Biobank is a large cohort study that includes data on plasma omega‐3 fatty acids at study entry and health outcomes during the follow‐up period.
Warda Tul Firdous, Philip C. Calder
wiley   +1 more source

Molecular Mapping of Atherosclerotic Plaques with MALDI Mass Spectrometry Imaging. [PDF]

open access: yesInt J Mol Sci
Leksa D   +8 more
europepmc   +1 more source

Susceptibility to unstable atherosclerotic plaques

open access: yesBiomedicine & Pharmacotherapy, 2001
openaire   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He   +4 more
wiley   +1 more source

Alzheimer's Disease: Mechanisms and Therapeutic Advances

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Alzheimer's disease involves Aβ/tau aggregation, neuroinflammation, BBB leakage, gut–brain dysfunction, and mitochondrial damage, causing neuronal loss. Nanodelivery enables combined small‐molecule and targeted therapies. Disease‐modifying biologics/chemicals, including anti‐Aβ antibodies, raise safety and access concerns. Exercise, cognitive training,
Gaoshuang Fu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy